KUSAI S AZIZ, M.D.
Medical Practice at Noble Ave, Visalia, CA

2010028, Nov 11, 2010

May 4, 2010

12/773028

Kusai Saadeldin Aziz - Visalia CA, US

A61K 31/015, A61M 37/00, A61K 31/047, A61K 31/20, A61K 31/01, A61P 9/10

604 20, 514764, 514738, 514558, 514762

A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in blood vessels of a patient is provided. The chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive product is administered at sites of the plaques formed in the patient's blood vessels. The chemical composition comprises, for example, one or more of d-limonene, propylene glycol, octanic acid, 2-octane, and glycerine. The chemical composition enables modification of the plaques by altering composition of the plaques. The modification comprises partial dissolution, complete dissolution or elimination of the plaques. The modification makes the plaques amenable to different forms of plaque treatment, for example, balloon angioplasty, stenting, atherectomy, etc. The modified plaques are eliminated from the body of the patient. The modification or elimination of the plaques facilitates treatment of cardiovascular diseases caused due to plaques formed in the blood vessels of the patient.

2010030, Dec 2, 2010

Jun 1, 2010

12/791007

Kusai Saadeldin Aziz - Visalia CA, US

A61N 1/00, A61B 5/0205, A61F 7/00, A61B 5/00, A61M 16/00

607 3, 600484, 607 96, 600301, 12820421

A system and method is provided for detection, forewarning, and rapid therapeutic treatment of a patient's ischemic and arrhythmic heart condition, congestive heart failure, respiratory failure, etc. The system comprises a chest casing of a form fitting material. The inner surface of the chest casing comprises electrocardiogram sensor electrodes, auscultation sensors, impedance sensor electrodes, etc. The electrocardiogram sensor electrodes detect abnormal electrocardiogram signals. The auscultation sensors record internal sounds at predefined cardiac and respiratory auscultation sensor points. The impedance sensor electrodes measure thoracic impedance across two or more points on the chest wall. A control unit is connected to the sensors for collecting and processing patient information. The control unit transmits the processed patient information to an external monitoring station. The chest casing comprises therapeutic delivery points for delivering therapeutic electrical dosages and different therapies, for example, cooling therapy, to the patient via therapeutic devices connected on the chest casing.

2011019, Aug 11, 2011

Apr 15, 2011

13/087520

Kusai Saadeldin Aziz - Visalia CA, US
Gary Michael Saxton - Sunnyvale CA, US

A61B 17/22, A61K 31/015, A61K 31/047, A61K 31/20, A61K 31/01, A61K 31/616, A61K 31/19, A61K 31/201, A61K 31/045, A61K 31/397, A61K 31/505, A61K 31/05, A61K 31/02, A61K 33/04, A61K 31/145, A61K 31/7076, A61K 31/277, A61K 38/16, A61P 9/00

606127, 514763, 514738, 514558, 514762, 514165, 514557, 514560, 514724, 51421002, 514275, 514733, 514758, 424701, 514642, 514 46, 514523, 514164, 514161, 514 11

A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in a patient's blood vessels is provided. A chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive substance is administered at sites of the plaques. The chemical composition comprises one or more of d-limonene, propylene glycol, octanoic acid, 2-octane, glycerine, acetylsalicylic acid, acetic acid, omega-3 fatty acids, ethanol, methanol, ezetimibe, rosuvastatin, resveratrol, lactic acid, gluconic acid, chloroform, carbon disulfide, dichloromethane, toluene, lauryldimethyl hydroxysultaine, and any combination thereof. The chemical composition enables modification of plaques by altering their composition. The modification comprises partial dissolution, complete dissolution, or elimination of the plaques, and makes the plaques amenable to different forms of plaque treatment. The modified plaques are eliminated from the patient's body. The modification or elimination of the plaques facilitates treatment of cardiovascular diseases caused due to plaques formed in the blood vessels.

2012015, Jun 21, 2012

Dec 12, 2011

13/323516

Kusai S. Aziz - Visalia CA, US
Ross Tsugita - Mountain View CA, US

Atherolysis Medical, Inc. - Visalia CA

A61M 5/168, A61M 1/00

604 28, 604 35, 604 31

An atherolysis catheter comprises a catheter body and one or more isolation balloons. A distal section of the body comprises infusion and aspiration ports in fluid communication with infusion and aspiration lumens for delivering and collecting fluids. A pump delivers infusate through the infusion lumen, and a valve in the infusion port controls release of the infusate into a target location in the vasculature.

2010006, Mar 18, 2010

Sep 15, 2009

12/559516

Kusai Saadeldin Aziz - Visalia CA, US

A61M 25/088

604528

A catheter assembly configurable to multiple shapes is provided. The catheter assembly comprises a detachable, interchangeable and configurable outer catheter and a detachable, interchangeable and flexible inner catheter. The shape of the outer catheter is configured to facilitate guiding of the inner catheter into an inner cavity of a patient's anatomy. The inner catheter is generally coaxial with the outer catheter. The second flexible distal end of the inner catheter enables the inner catheter to engage the inner cavity of the patient's anatomy. A locking element is provided for securing the inner catheter to the outer catheter, when the second flexible distal end of the inner catheter engages the inner cavity of the patient's anatomy to allow equipment or material to be introduced into the inner cavity. The catheter assembly is configured and manipulated to fit inner cavities of multiple anatomies for enabling a medical practitioner to perform medical procedures.